失代偿期肝硬化再代偿的研究现状及进展

摘要/Abstract

摘要： 传统观点认为,肝硬化由代偿期进展至失代偿期是一个不可逆的病理过程。近年来,随着病因得到有效控制或清除后肝脏结构与功能部分恢复的现象被逐渐证实,传统认识正受到越来越多的挑战。Baveno Ⅶ共识提出了肝硬化再代偿的判定标准,为开展相关临床研究的规范化提供了重要依据。本文系统梳理了失代偿期肝硬化再代偿的研究进展,旨在加深对其机制与临床意义的理解,推动该领域研究的进一步发展,并为临床实践提供参考。

关键词: 肝硬化, 失代偿期, 再代偿, Baveno Ⅶ共识

黄冬波, 刘韬韬. 失代偿期肝硬化再代偿的研究现状及进展[J]. 肝脏, 2025, 30(11): 1456-1460.

/ 推荐

参考文献

[1] Schuppan D, Afdhal N H. Liver cirrhosis[J]. Lancet, 2008, 371(9615):838-851.
[2] De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4):959-974.
[3] 中华医学会消化病学分会. 中国肝硬化临床诊治共识意见[J]. 中华消化杂志, 2023, 43(4):227-247.
[4] Premkumar M, Dhiman R K, Duseja A, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: Prospective cohort study from a hepatitis C virus elimination program[J]. Gastroenterology, 2024, 167(7):1429-1445.
[5] Krassenburg L A P, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity[J]. J Hepatol, 2021, 74(5):1053-1063.
[6] Sánchez-Torrijos Y, Fernández-Alvarez P, Rosales J M, et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C[J]. J Hepatol, 2025, 83(3):652-661.
[7] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6):1564-1572.
[8] Deng Y, Kang H Y, Xiang H L, et al. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis[J]. JHEP Rep, 2024, 6(7):101091.
[9] Hui V W K, Wong G L H, Wong V W S, et al. Baveno Ⅶ criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis[J]. JHEP Rep, 2023, 5(9):100814.
[10] Hofer B S, Simbrunner B, Hartl L, et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis[J]. Clin Gastroenterol Hepatol, 2023, 21(9):2308-2317.e7.
[11] Pose E, Torrents A, Reverter E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement[J]. J Hepatol, 2021, 75(2):275-283.
[12] Hofer B S, Simbrunner B, Hartl L, et al. Hepatic recompensation according to Baveno Ⅶ criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023, 43(10):2220-2231.
[13] Jagtap N, Kalapala R, Katakwar A, et al. Endoscopic sleeve gastroplasty: Minimally invasive treatment for non-alcoholic fatty liver disease and obesity[J]. Indian J Gastroenterol, 2021, 40(6):572-579.
[14] Wang Z Y, Sheng L, Yang Y, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: Real-world experience and a comprehensive review[J]. Clin Rev Allergy Immunol, 2017, 52(3):424-435.
[15] Hofer B S, Burghart L, Halilbasic E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis[J]. Aliment Pharmacol Ther, 2024, 59(8):962-972.
[16] Tiede A, Maasoumy B. TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure?[J]. Clin Mol Hepatol, 2025, 31(2):e176-e179.
[17] Tiede A, Stockhoff L, Liu Z, et al. Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis[J]. Clin Mol Hepatol, 2025, 31(1):240-255.
[18] Kornfehl A, Tiede A, Hemetsberger P, et al. Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis[J]. JHEP Rep, 2024, 7(4):101308.
[19] Sánchez J, González S, Poyatos P, et al. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis[J]. Liver Int, 2024, 44(11):3072-3082.
[20] El-Sherif O, Jiang Z G, Tapper E B, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection[J]. Gastroenterology, 2018, 154(8):2111-2121.e8.
[21] Kim T H, Um S H, Lee Y S, et al. Determinants of recompensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy[J]. Aliment Pharmacol Ther, 2022, 55(1):83-96.
[22] Vutien P, Kim N J, Moon A M, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication[J]. Aliment Pharmacol Ther, 2024, 59(3):361-371.
[23] Singal A K, Panneerselvam D, Arab J P, et al. Delisting from liver transplant list for improvement and recompensation among decompensated patients at one year[J]. Am J Gastroenterol, 2024, 120(9):2086-2092.